Novartis Bolsters Hep C Pipeline With Human Genome Sciences Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement gives Novartis rights to Albuferon, a Phase III interferon. In a separate agreement with Cytopia, Novartis will develop JAK3 inhibitors for autoimmune diseases and transplant rejection.
You may also be interested in...
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.
Human Genome Sciences Achieves Milestone For Albuferon Phase II Completion
HGS expects data from ACHIEVE pivotal program by spring 2009; global filings by fall 2009.
Novartis/Human Genome Sciences Launch Second Phase III Albuferon Trial
Firms plan 2009 regulatory filings for the hepatitis C treatment.